MoonLake Immunotherapeutics (MLTX) Short term Debt (2021)
MoonLake Immunotherapeutics' (MLTX) quarterly Short term Debt came in at $15.0 million in Q4 2021.
MoonLake Immunotherapeutics (MLTX) Short term Debt (2021) Analysis & Trends
MoonLake Immunotherapeutics' Short term Debt history runs 1 years deep, the most recent figure standing at $15.0 million for Q4 2021.
- On a quarterly basis, Short term Debt changed N/A year-over-year to $15.0 million in Q4 2021; TTM through Dec 2021 was $15.0 million, a N/A change from a year earlier, with the FY2021 full-year figure at $15.0 million, changed N/A from the prior year.
- Short term Debt was little changed at $15.0 million in Q4 2021 per MLTX's latest filing.
- Across five years, Short term Debt topped out at $15.0 million in Q4 2021 and bottomed at $15.0 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | MoonLake Immunotherapeutics | 1.38 Bn | 1.02 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 15.00 Mn |